Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 53 of 266 for:    Pancreatic Cancer AND Resectable

Tumor Registry Pancreatic Cancer (TPK)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02089269
Recruitment Status : Active, not recruiting
First Posted : March 17, 2014
Last Update Posted : August 6, 2019
Sponsor:
Information provided by (Responsible Party):
iOMEDICO AG

Brief Summary:
The registry aims to collect and analyse information on the antineoplastic treatment of patients with unresectable locally advanced or metastatic pancreatic cancer, treated in palliative intention (cohort 1) and patients with localized, resectable pancreatic cancer treated in neo-adjuvant or adjuvant intention (cohort 2) in daily routine practice in Germany. The registry will follow up patients for two years. It will identify common sequences of treatments used as well as changes in the treatment of the disease. Health-related quality of life will be analysed during the course of the treatment (PanLife). Based on the available data a prognostic score will be developed.

Condition or disease
Pancreas Cancer

Layout table for study information
Study Type : Observational
Actual Enrollment : 1725 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Clinical Registry on Treatment Reality and Sequential Treatments of Patients With Resectable or Locally Advanced/Metastatic Pancreatic Cancer in Real-life Practice in Germany
Study Start Date : December 2013
Estimated Primary Completion Date : March 2020
Estimated Study Completion Date : March 2020

Resource links provided by the National Library of Medicine


Group/Cohort
Cohort 1
1,625 patients with unresectable locally advanced or metastatic pancreatic cancer, treated in palliative intention
Cohort 2
100 patients with localized, resectable pancreatic cancer treated in neo-adjuvant or adjuvant intention



Primary Outcome Measures :
  1. Treatment reality in Germany [ Time Frame: over 5 years ]
    description of treatments selected for patients per line of therapy over the course of the project



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with pancreatic cancer undergoing antineoplastic treatment.
Criteria

Inclusion Criteria:

  • resectable or locally advanced/metastatic pancreatic cancer
  • 18 years and older
  • Antineoplastic treatment
  • Date of consent no later than 2 weeks after start of first-line treatment

Exclusion Criteria:

  • No pancreatic cancer
  • Below 18 years and older
  • No antineoplastic treatment
  • Date of consent later than 2 weeks after start of first-line treatment

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02089269


Locations
Layout table for location information
Germany
iOMEDICO
Freiburg, BW, Germany
Sponsors and Collaborators
iOMEDICO AG
Investigators
Layout table for investigator information
Study Chair: Susanna Hegewisch-Becker, Prof. MD Outpatient Clinic, Hamburg
Study Chair: Hofheinz Ralf, Prof. MD University Clinic, Mannheim

Layout table for additonal information
Responsible Party: iOMEDICO AG
ClinicalTrials.gov Identifier: NCT02089269     History of Changes
Other Study ID Numbers: iOM-01281
Tumorregister Pankreaskarzinom ( Other Identifier: iOMEDICO )
First Posted: March 17, 2014    Key Record Dates
Last Update Posted: August 6, 2019
Last Verified: August 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by iOMEDICO AG:
pancreatic neoplasms
neoplasms
advanced pancreatic cancer
localized, resectable pancreatic cancer
registry
health services research
epidemiology
Germany
palliative treatment
palliative care
adjuvant treatment
Additional relevant MeSH terms:
Layout table for MeSH terms
Pancreatic Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Endocrine Gland Neoplasms
Digestive System Diseases
Pancreatic Diseases
Endocrine System Diseases